PEARL BIO, INC.

Cambridge, MA · Founded 2020 · Biotech · Private

Engineered biological systems that use modified ribosomes and translation apparatus to synthesize sequence-defined biopolymers incorporating non-canonical amino acids at scale

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · pearlbio.com

Sector: Biotech
Headquarters: Cambridge, MA
Founded: 2020
Latest Form D: $4.1M, Oct 2021
Total capital: $8.3M

Federal grants: $2.2M; 6 awards · 2023–2026; Rank in peer group#434 of 514
Private capital raised: $4.1M; 1 Form D · last Oct 2021; 61 months since last filing
Federal contracts: $1.9M; 2 awards · Defense; Rank in Biotech#137 of 4373
Granted patents: None on recordNo USPTO grants. Applications publish after 18 months.

Capital timeline

Latest events

Apr 2026Federal contractDefense · Small Business Technology Transfer Research (STTR) Services Phase I Effort Titled Scalable Production Of Sequence-defined Biopolymers Containing Aramids In Genomically Recoded Systems.$250K
Mar 2026Federal grantDefense · Phase I · Small Business Technology Transfer Research (STTR) Services Phase I Effort Titled Scalable Production Of Sequence-defined Biopolymers Containing Aramids In Genomically Recoded Systems.$250K
May 2024Federal grantHealth and Human S · Phase I · Development of Programmable Nanobodies for Multi-functionalized Biologics$295K
May 2024Federal grantDefense · Phase II · Small Business Technology Transfer Research Program$850K
May 2024Federal contractDefense · Small Business Technology Transfer Research Program$1.7M
Feb 2024Federal grantHealth and Human S · Phase I · Development of next-generation biologics programmed with multifunctional synthetic chemistries$275K
Aug 2023Federal grantNSF · Phase I · SBIR Phase I:Consolidated platform to engineer and produce novel biopolymers for improved biologics$274K
Oct 2021Private capital raisedForm D · SEC · 1st filing$4.1M

Show 1 earlier federal award

Mar 2023Federal grantDefense · Phase I · Scalable production of sequence-defined biopolymers containing multiple distinct non-canonical amino acids in recoded cell and cell-free systems$250K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 514 peers

Line = median

Biotech · Molecule

Federal grantsBelow median

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings

Farren IsaacsExecutive Officer, DirectorNamed in SEC Form D filings
Merton GollaherExecutive OfficerNamed in SEC Form D filings
Michael JewettExecutive Officer, DirectorNamed in SEC Form D filings

What it has protected

No granted patents are on record.

USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.

Checked: USPTO granted patents and published applications · Oct 23, 2026

MerusSimilar federal contract value in Biotech · $2.1M in contracts
GENCIRQ, INC.Similar federal contract value in Biotech · $2M in contracts
BUFFALO BIOLABS, LLCSimilar federal contract value in Biotech · $2M in contracts
GLYCAN THERAPEUTICS CORPORATIONSimilar federal contract value in Biotech · $1.9M in contracts
NAVIPOINT GENOMICS LLCSimilar federal contract value in Biotech · $1.9M in contracts
IDBIOLOGICS INCSimilar federal contract value in Biotech · $1.9M in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.